Alex Thompson
Stock Analyst at Stifel
(2.74)
# 2,070
Out of 5,049 analysts
38
Total ratings
56.67%
Success rate
4.11%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Alex Thompson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ANAB AnaptysBio | Maintains: Buy | $55 → $80 | $36.04 | +121.98% | 1 | Oct 29, 2025 | |
| DNTH Dianthus Therapeutics | Maintains: Buy | $52 → $65 | $34.03 | +91.01% | 2 | Sep 12, 2025 | |
| TVTX Travere Therapeutics | Maintains: Hold | $20 → $25 | $34.53 | -27.60% | 4 | Sep 12, 2025 | |
| ASND Ascendis Pharma | Maintains: Buy | $212 → $254 | $200.98 | +26.38% | 3 | Aug 8, 2025 | |
| CGEM Cullinan Therapeutics | Reinstates: Buy | $22 | $7.81 | +181.69% | 1 | Jun 11, 2025 | |
| KYMR Kymera Therapeutics | Reinstates: Buy | $55 | $59.72 | -7.90% | 1 | May 20, 2025 | |
| AVTX Avalo Therapeutics | Initiates: Buy | $36 | $16.67 | +115.96% | 1 | Mar 25, 2025 | |
| CRNX Crinetics Pharmaceuticals | Initiates: Buy | $60 | $42.85 | +40.02% | 1 | Mar 25, 2025 | |
| ORKA Oruka Therapeutics | Initiates: Buy | $49 | $26.18 | +87.17% | 1 | Oct 11, 2024 | |
| ARGX argenx SE | Maintains: Buy | $485 → $500 | $826.23 | -39.48% | 4 | Jun 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $36 → $54 | $23.78 | +127.08% | 2 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $6 → $2 | $8.23 | -75.70% | 5 | Dec 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $66 → $69 | $10.20 | +576.47% | 2 | Dec 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $2 → $1 | $2.56 | -60.94% | 4 | Dec 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $40 | $23.15 | +72.79% | 2 | Sep 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $320 | $29.35 | +990.29% | 1 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $28 → $34 | $23.78 | +42.98% | 2 | Jul 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $33 | $1.67 | +1,876.05% | 1 | Dec 14, 2022 |
AnaptysBio
Oct 29, 2025
Maintains: Buy
Price Target: $55 → $80
Current: $36.04
Upside: +121.98%
Dianthus Therapeutics
Sep 12, 2025
Maintains: Buy
Price Target: $52 → $65
Current: $34.03
Upside: +91.01%
Travere Therapeutics
Sep 12, 2025
Maintains: Hold
Price Target: $20 → $25
Current: $34.53
Upside: -27.60%
Ascendis Pharma
Aug 8, 2025
Maintains: Buy
Price Target: $212 → $254
Current: $200.98
Upside: +26.38%
Cullinan Therapeutics
Jun 11, 2025
Reinstates: Buy
Price Target: $22
Current: $7.81
Upside: +181.69%
Kymera Therapeutics
May 20, 2025
Reinstates: Buy
Price Target: $55
Current: $59.72
Upside: -7.90%
Avalo Therapeutics
Mar 25, 2025
Initiates: Buy
Price Target: $36
Current: $16.67
Upside: +115.96%
Crinetics Pharmaceuticals
Mar 25, 2025
Initiates: Buy
Price Target: $60
Current: $42.85
Upside: +40.02%
Oruka Therapeutics
Oct 11, 2024
Initiates: Buy
Price Target: $49
Current: $26.18
Upside: +87.17%
argenx SE
Jun 24, 2024
Maintains: Buy
Price Target: $485 → $500
Current: $826.23
Upside: -39.48%
Mar 26, 2024
Reiterates: Buy
Price Target: $36 → $54
Current: $23.78
Upside: +127.08%
Dec 18, 2023
Maintains: Hold
Price Target: $6 → $2
Current: $8.23
Upside: -75.70%
Dec 18, 2023
Maintains: Buy
Price Target: $66 → $69
Current: $10.20
Upside: +576.47%
Dec 18, 2023
Maintains: Hold
Price Target: $2 → $1
Current: $2.56
Upside: -60.94%
Sep 13, 2023
Reiterates: Buy
Price Target: $40
Current: $23.15
Upside: +72.79%
Aug 9, 2023
Initiates: Buy
Price Target: $320
Current: $29.35
Upside: +990.29%
Jul 18, 2023
Maintains: Buy
Price Target: $28 → $34
Current: $23.78
Upside: +42.98%
Dec 14, 2022
Initiates: Buy
Price Target: $33
Current: $1.67
Upside: +1,876.05%